{"id":"W2276028032","doi":"10.1007/s13300-016-0155-1","title":"A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus","year":2016,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sheridan College; Public Health Ontario","funders":"AstraZeneca","keywords":"Exenatide; Medicine; Lixisenatide; Tolerability; Dulaglutide; Metformin; Liraglutide; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Glucagon-like peptide 1 receptor; Discontinuation; Type 2 Diabetes Mellitus; Pharmacology; Diabetes mellitus; Adverse effect; Endocrinology; Agonist; Insulin; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02054588,0.003303875,0.01641982,0.005326225,0.0006898075,0.00311589,0.002214788,0.002660054,0.005323919],"category_scores_gemma":[0.03724449,0.00139677,0.05937625,0.005677782,0.0006194805,0.00189868,0.001542115,0.002954127,0.0003644492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002350628,"about_ca_system_score_gemma":0.002325076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009423213,"about_ca_topic_score_gemma":0.01071965,"domain_scores_codex":[0.9769283,0.01683857,0.00226958,0.002279179,0.001238143,0.0004462241],"domain_scores_gemma":[0.972263,0.02298319,0.002421239,0.0009383184,0.001003352,0.0003908955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.008273914,0.00004137353,0.005020826,0.03423295,0.9450324,0.0001059757,0.00002625256,0.002381626,0.0001480444,0.0001289021,0.0005738452,0.004033906],"study_design_scores_gemma":[0.002314657,0.0003302559,0.002860924,0.001808412,0.9901984,0.00004919267,0.0000138768,0.001475644,0.00005851889,0.0002970647,0.0005738142,0.00001925428],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05597467,0.9282539,0.005952745,0.001407525,0.001174431,0.001069318,0.00421669,0.0002396336,0.001711231],"genre_scores_gemma":[0.819625,0.1627694,0.007494937,0.001815588,0.00060041,0.002629131,0.003758935,0.0001134261,0.00119321],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02054588,"threshold_uncertainty_score":0.1086583,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1266099849112865,"score_gpt":0.3423086737592977,"score_spread":0.2156986888480112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}